Dupilumab for STAT3-Hyper-IgE Syndrome With Refractory Intestinal Complication.

Medicine and Dentistry

• Complication 100%
• Immunoglobulin E 100%
• Diarrhea 100%
• Syndrome 100%
• Patient 75%
• Hyperimmune Globulin 75%
• Skin 50%
• Immune Deficiency 50%
• Eczema 50%
• Gastrointestinal Distress 50%
• Intestine Perforation 50%
• Therapeutic Procedure 25%
• Surgery 25%
• Life 25%
• Serum 25%
• Antibiotics 25%
• Gut 25%
• Plummer-Vinson Syndrome 25%
• Steroid Treatment 25%
• Threat 25%
• Dermatitis 25%
• Abscess 25%
• Man 25%
• Next Generation Sequencing 25%
• Abdominal Pain 25%
• Gastroesophageal Reflux 25%
• Isoprenaline 25%
• Intravenous Immunoglobulin Therapy 25%
• Immunomodulating Agent 25%
• Respiratory Tract Infection 25%

Immunology and Microbiology

• STAT3 100%
• Hyper IgE Syndrome 100%
• Dupilumab 100%
• Skin 60%
• Hyperimmunoglobulin E Syndrome 60%
• Inflammation 40%
• Immunodeficiency 40%
• Life 20%
• Immunoglobulin E 20%
• Mutation 20%
• Colon 20%
• Time 20%
• Eczema 20%
• Immunoglobulin Blood Level 20%
• Immunomodulating Drugs 20%
• Dermatitis 20%
• Esophagitis 20%